Industry and Innovation
Structural Biology is the foundation on which a wide range of innovative projects in industry are built, including projects aiming to tackle critical societal challenges within medicine and sustainability such as the development of new drug molecules or engineering of novel enzymes for green chemistry. In order to ensure maximum impact of the state-of-the-art research and technology development being driven forward by ISBUC scientists, ISBUC builds vital bridges between structural biologists working in academia and industry in Copenhagen and the surrounding regions. ISBUC also supports scientists at all levels who wish to make the leap from academic to entrepreneur. These activities are developed in collaboration between the ISBUC Steering Committee and the ISBUC Industry Advisory Board, who you can meet below.
ISBUC Industry Advisory Board
Industry and Innovation Events
Innovation News and Prizes
Novo Nordisk buys CBMR biotech spinout to acquire their novel approach for treating obesity and type 2 diabetes
30 August 2023
Kristian Strømgaard receives the Danish Academy of Natural Sciences’ Industry Prize 2023
1 December 2023
Professor Thue W. Schwartz wins UCPH Innovation Prize 2023
13 November 2023
A founding member of CBMR, Professor Thue W. Schwartz is a pioneering fundamental researcher and co-founder of countless spinouts.
Novo Nordisk Foundation appoints three new innovation ambassadors
July 1st, 2021
Kristian Strømgaard (left) from the University of Copenhagen received an innovation grant of DKK 6 million from the Novo Nordisk Foundation.
New startup company to refine gene editing tool for diagnostics and treatment
19 November 2019
Startups and Spinout Companies
Mette Rosenkilde (Co-founder)
Antag Therapeutics is a biotechnology company pioneering personal and flexible obesity treatment through GIP receptor antagonism.
Mette Rosenkilde (Co-founder and Member of the Board of Directors)
Henriette Elisabeth Autzen (Co-Founder and CSO)
The delivery platform developed by Polyceutix can deliver effective drugs to where they are needed, at the doses required, and facilitating the optimal environment for their effect.
Guillermo Montoya (Founder and Board of Directors Member)
Twelve Bio has advanced foundational insights from X-ray crystallography and cryogenic electron microscopy to further engineer and evolve CRISPR-Cas12a into wholly novel sequences with unique properties useful for a range of DNA editing strategies. Twelve Bio was acquired by Ensoma in February 2023.
Thue W. Schwartz (Scientific Godfather)
Embark Laboratories is pioneering novel therapeutic solutions for cardiometabolic indications, with the goal of delivering safe and well-tolerated strategies that leverage energy expenditure, insulin sensitization, and appetite control, while preserving lean mass.
Mette Rosenkilde (Co-founder)
Synklino develops safe and efficacious drug for the elimination of cytomegalovirus in high-risk immunocompromised patients and transplant recipients.
Ulrik Gether (Co-founder and Consultant) and Kenneth Lindegaard Madsen (Co-founder and CDO)
Zyneyro is developing next-generation therapies for chronic pain without the typical side effects. The lead peptide program, ZYN01, aims to deliver rapid, reversible and safer pain relief without the limitations of current treatments.